Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 27.13
+1.19 (4.59%)
At close: Feb 13, 2026
SHA:688319 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 706.38 | 586.1 | 494.29 | 546.68 | 485.29 | 318.91 |
Other Revenue | 2.75 | 2.75 | 1.83 | 0.8 | 1.86 | 1.2 |
| 709.13 | 588.86 | 496.12 | 547.48 | 487.15 | 320.11 | |
Revenue Growth (YoY) | 33.68% | 18.69% | -9.38% | 12.38% | 52.18% | 78.72% |
Cost of Revenue | 44.34 | 29.77 | 36.73 | 43.01 | 28.36 | 17.84 |
Gross Profit | 664.79 | 559.09 | 459.39 | 504.48 | 458.79 | 302.27 |
Selling, General & Admin | 437.58 | 389.32 | 336.12 | 352.06 | 296.33 | 223.76 |
Research & Development | 129.72 | 134.23 | 114.73 | 121.99 | 56.36 | 42.73 |
Other Operating Expenses | 8.5 | 3.72 | 3.32 | 3.55 | 3.21 | 2.32 |
Operating Expenses | 586.53 | 537.47 | 455.89 | 489.78 | 364.9 | 274.3 |
Operating Income | 78.26 | 21.62 | 3.51 | 14.7 | 93.89 | 27.97 |
Interest Expense | -14.89 | -14.46 | -7.18 | -5.07 | -1.23 | -0.57 |
Interest & Investment Income | 4.57 | 5.36 | 3.6 | 7.55 | 5.19 | 0.59 |
Other Non Operating Income (Expenses) | -1.26 | -0.25 | 0.07 | -0.21 | -0.19 | -0.43 |
EBT Excluding Unusual Items | 66.68 | 12.28 | -0.01 | 16.97 | 97.67 | 27.56 |
Gain (Loss) on Sale of Assets | -0.02 | -0.03 | -0.15 | -0.15 | -0.05 | 0 |
Asset Writedown | -8.63 | - | - | - | - | - |
Other Unusual Items | 18.58 | 10.06 | 15.77 | 26.83 | 9.57 | 8.57 |
Pretax Income | 76.61 | 22.3 | 15.62 | 43.65 | 107.19 | 36.13 |
Income Tax Expense | 13.66 | 6.58 | 4.18 | 17.07 | -0.77 | - |
Earnings From Continuing Operations | 62.95 | 15.72 | 11.44 | 26.58 | 107.96 | 36.13 |
Minority Interest in Earnings | 1.26 | 5.04 | 6.11 | - | - | - |
Net Income | 64.21 | 20.76 | 17.56 | 26.58 | 107.96 | 36.13 |
Net Income to Common | 64.21 | 20.76 | 17.56 | 26.58 | 107.96 | 36.13 |
Net Income Growth | - | 18.24% | -33.95% | -75.38% | 198.82% | - |
Shares Outstanding (Basic) | 405 | 405 | 405 | 405 | 385 | 365 |
Shares Outstanding (Diluted) | 405 | 405 | 405 | 405 | 385 | 365 |
Shares Change (YoY) | -0.46% | -0.01% | 0.07% | 5.22% | 5.61% | 0.89% |
EPS (Basic) | 0.16 | 0.05 | 0.04 | 0.07 | 0.28 | 0.10 |
EPS (Diluted) | 0.16 | 0.05 | 0.04 | 0.07 | 0.28 | 0.10 |
EPS Growth | - | 18.25% | -33.99% | -76.61% | 182.95% | - |
Free Cash Flow | -42.56 | -217.05 | -125.88 | -225.24 | -29.75 | -17.76 |
Free Cash Flow Per Share | -0.10 | -0.54 | -0.31 | -0.56 | -0.08 | -0.05 |
Dividend Per Share | - | - | 0.038 | - | - | - |
Gross Margin | 93.75% | 94.94% | 92.60% | 92.14% | 94.18% | 94.43% |
Operating Margin | 11.04% | 3.67% | 0.71% | 2.69% | 19.27% | 8.74% |
Profit Margin | 9.05% | 3.52% | 3.54% | 4.85% | 22.16% | 11.29% |
Free Cash Flow Margin | -6.00% | -36.86% | -25.37% | -41.14% | -6.11% | -5.55% |
EBITDA | 106.84 | 49.57 | 30.62 | 40 | 116.93 | 45.6 |
EBITDA Margin | 15.07% | 8.42% | 6.17% | 7.31% | 24.00% | 14.24% |
D&A For EBITDA | 28.58 | 27.95 | 27.11 | 25.3 | 23.04 | 17.62 |
EBIT | 78.26 | 21.62 | 3.51 | 14.7 | 93.89 | 27.97 |
EBIT Margin | 11.04% | 3.67% | 0.71% | 2.69% | 19.27% | 8.74% |
Effective Tax Rate | 17.82% | 29.52% | 26.74% | 39.11% | - | - |
Revenue as Reported | 709.13 | 588.86 | 496.12 | 547.48 | 487.15 | 320.11 |
Advertising Expenses | - | 264.73 | 224.9 | 248.75 | 212.96 | 160.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.